Cargando…

Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma

The aim of this pilot study was to determine the plasma levels of osteopontin (OPN) and vascular endothelial growth factor (VEGF) and find possible association between them and main clinical features and parameters of tumor burden in patient with multiple myeloma (MM). Plasma levels of OPN and VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Valković, Toni, Babarović, Emina, Lučin, Ksenija, Štifter, Sanja, Aralica, Merica, Pećanić, Sanja, Seili-Bekafigo, Irena, Duletić-Načinović, Antica, Nemet, Damir, Jonjić, Nives
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065766/
https://www.ncbi.nlm.nih.gov/pubmed/24995304
http://dx.doi.org/10.1155/2014/513170
_version_ 1782322141506568192
author Valković, Toni
Babarović, Emina
Lučin, Ksenija
Štifter, Sanja
Aralica, Merica
Pećanić, Sanja
Seili-Bekafigo, Irena
Duletić-Načinović, Antica
Nemet, Damir
Jonjić, Nives
author_facet Valković, Toni
Babarović, Emina
Lučin, Ksenija
Štifter, Sanja
Aralica, Merica
Pećanić, Sanja
Seili-Bekafigo, Irena
Duletić-Načinović, Antica
Nemet, Damir
Jonjić, Nives
author_sort Valković, Toni
collection PubMed
description The aim of this pilot study was to determine the plasma levels of osteopontin (OPN) and vascular endothelial growth factor (VEGF) and find possible association between them and main clinical features and parameters of tumor burden in patient with multiple myeloma (MM). Plasma levels of OPN and VEGF were determined in 44 newly diagnosed MM patients and 24 healthy persons by ELISA method. These values were compared with the presence of anemia, renal dysfunction, and bone lesions as myeloma related clinical manifestations and with serum beta-2 microglobulin and Durie-Salmon clinical stage as prognosticators related to tumor mass. The value of OPN was significantly higher in MM patients with evident bone lesions (P = 0.03) and there was also a positive correlation with serum beta-2 microglobulin (r = 0.366; P = 0.04). Furthermore, patients with lower Durie-Salmon stage had significantly lower OPN and VEGF levels (P = 0.05; P = 0.04, resp.). Our preliminary results found positive association between plasma level of OPN, tumor burden, and bone destruction. Further analysis should provide information about the possible use of OPN as useful clinical biomarker for monitoring bone disease and tumor mass, as well as a prognostic factor, or a possible target for pharmacological intervention.
format Online
Article
Text
id pubmed-4065766
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40657662014-07-03 Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma Valković, Toni Babarović, Emina Lučin, Ksenija Štifter, Sanja Aralica, Merica Pećanić, Sanja Seili-Bekafigo, Irena Duletić-Načinović, Antica Nemet, Damir Jonjić, Nives Biomed Res Int Research Article The aim of this pilot study was to determine the plasma levels of osteopontin (OPN) and vascular endothelial growth factor (VEGF) and find possible association between them and main clinical features and parameters of tumor burden in patient with multiple myeloma (MM). Plasma levels of OPN and VEGF were determined in 44 newly diagnosed MM patients and 24 healthy persons by ELISA method. These values were compared with the presence of anemia, renal dysfunction, and bone lesions as myeloma related clinical manifestations and with serum beta-2 microglobulin and Durie-Salmon clinical stage as prognosticators related to tumor mass. The value of OPN was significantly higher in MM patients with evident bone lesions (P = 0.03) and there was also a positive correlation with serum beta-2 microglobulin (r = 0.366; P = 0.04). Furthermore, patients with lower Durie-Salmon stage had significantly lower OPN and VEGF levels (P = 0.05; P = 0.04, resp.). Our preliminary results found positive association between plasma level of OPN, tumor burden, and bone destruction. Further analysis should provide information about the possible use of OPN as useful clinical biomarker for monitoring bone disease and tumor mass, as well as a prognostic factor, or a possible target for pharmacological intervention. Hindawi Publishing Corporation 2014 2014-06-04 /pmc/articles/PMC4065766/ /pubmed/24995304 http://dx.doi.org/10.1155/2014/513170 Text en Copyright © 2014 Toni Valković et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Valković, Toni
Babarović, Emina
Lučin, Ksenija
Štifter, Sanja
Aralica, Merica
Pećanić, Sanja
Seili-Bekafigo, Irena
Duletić-Načinović, Antica
Nemet, Damir
Jonjić, Nives
Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
title Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
title_full Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
title_fullStr Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
title_full_unstemmed Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
title_short Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
title_sort plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065766/
https://www.ncbi.nlm.nih.gov/pubmed/24995304
http://dx.doi.org/10.1155/2014/513170
work_keys_str_mv AT valkovictoni plasmalevelsofosteopontinandvascularendothelialgrowthfactorinassociationwithclinicalfeaturesandparametersoftumorburdeninpatientswithmultiplemyeloma
AT babarovicemina plasmalevelsofosteopontinandvascularendothelialgrowthfactorinassociationwithclinicalfeaturesandparametersoftumorburdeninpatientswithmultiplemyeloma
AT lucinksenija plasmalevelsofosteopontinandvascularendothelialgrowthfactorinassociationwithclinicalfeaturesandparametersoftumorburdeninpatientswithmultiplemyeloma
AT stiftersanja plasmalevelsofosteopontinandvascularendothelialgrowthfactorinassociationwithclinicalfeaturesandparametersoftumorburdeninpatientswithmultiplemyeloma
AT aralicamerica plasmalevelsofosteopontinandvascularendothelialgrowthfactorinassociationwithclinicalfeaturesandparametersoftumorburdeninpatientswithmultiplemyeloma
AT pecanicsanja plasmalevelsofosteopontinandvascularendothelialgrowthfactorinassociationwithclinicalfeaturesandparametersoftumorburdeninpatientswithmultiplemyeloma
AT seilibekafigoirena plasmalevelsofosteopontinandvascularendothelialgrowthfactorinassociationwithclinicalfeaturesandparametersoftumorburdeninpatientswithmultiplemyeloma
AT duleticnacinovicantica plasmalevelsofosteopontinandvascularendothelialgrowthfactorinassociationwithclinicalfeaturesandparametersoftumorburdeninpatientswithmultiplemyeloma
AT nemetdamir plasmalevelsofosteopontinandvascularendothelialgrowthfactorinassociationwithclinicalfeaturesandparametersoftumorburdeninpatientswithmultiplemyeloma
AT jonjicnives plasmalevelsofosteopontinandvascularendothelialgrowthfactorinassociationwithclinicalfeaturesandparametersoftumorburdeninpatientswithmultiplemyeloma